Cancer Breakthrough Fund Blends VC and Charity to Fuel Canadian Innovation

TORONTO, ON – May 05, 2026 – By Kathleen Cook

A novel alliance between venture capital and two of Canada’s most prominent cancer charities has resulted in an oversubscribed new fund, signaling a major shift in the country's fight against cancer. Lumira Ventures, the Terry Fox Foundation, and the Canadian Cancer Society announced the successful first close of the Cancer Breakthrough Fund, a mission-driven venture capital initiative that has already surpassed its initial $30 million goal.

The fund, a first of its kind in Canada, aims to bridge the critical gap between scientific discovery and patient-ready treatments. With initial commitments now pushing the partners to aim for a new hard cap of $50 million, the fund is poised to inject vital capital into Canada’s most promising cancer-focused companies. It represents a powerful new strategy: combining the financial acumen and company-building expertise of venture capital with the deep scientific networks and philanthropic mission of charities that have been at the forefront of cancer research for decades.

A New Model for a Stubborn Problem

For years, Canada's life sciences sector has grappled with a well-documented challenge known as the "valley of death." The country invests approximately $500 million annually in cancer research, with the vast majority supporting early-stage discovery. While this fosters a vibrant academic research environment, a critical funding gap often stalls the progress of promising innovations before they can be commercialized and reach patients. This frequently leads to Canadian intellectual property being sold or developed abroad.

The Cancer Breakthrough Fund is designed to directly address this structural weakness. By creating a hybrid model that marries philanthropic purpose with for-profit investment, the partners are building a new bridge across that valley.

"Surpassing our initial target and closing oversubscribed in just twelve months is a powerful validation that the market recognizes both the strength of this mission-driven investment opportunity and the urgent need for cross-sector collaboration in Canada," said Peter van der Velden, Executive Chairman of Lumira Ventures. "The Fund was built on the belief that uniting philanthropic mission with venture capital expertise to support cancer innovation would offer the potential to unlock transformative outcomes for patients."

This model, while more common in the United States, is a significant evolution for Canada. It breaks down the traditional silos that have separated non-profit research funding from private-sector commercialization. The fund will leverage the vast networks of researchers and oncologists supported by the Terry Fox Foundation and Canadian Cancer Society to identify and vet the most scientifically sound investment opportunities, ensuring capital is deployed for maximum impact.

Bridging the Gap from Lab to Patient

The ultimate goal of this collaboration is to accelerate the delivery of new, life-saving therapies to Canadians. The fund’s mission resonates deeply with the legacies of its charitable partners, organizations built on the promise of turning research into hope.

"Just as Terry unites all Canadians, the Cancer Breakthrough Fund now brings together two of Canada's leading cancer charities with Lumira's venture capital expertise to transform the most innovative research in Canada into real impact for patients," stated Michael Mazza, Chief Executive Officer of the Terry Fox Foundation. He emphasized that true breakthroughs happen when scientists, entrepreneurs, and investors collaborate to translate innovation into products.

The Canadian Cancer Society, which has joined as a foundational partner, echoed this patient-centric focus. "Canadians facing cancer deserve access to the newest and best care as quickly as possible—and that requires stronger support for scientific innovation and commercialization," said Andrea Seale, Chief Executive Officer of the Canadian Cancer Society. "This kind of cross-sector collaboration is essential to driving real progress against cancer in Canada."

By providing crucial funding for clinical trials and product development within Canada, the fund aims to not only keep Canadian innovation at home but also give Canadian patients earlier access to cutting-edge treatments developed in their own backyard.

Bolstering Canada's Biotech Backbone

Beyond its immediate impact on cancer treatment, the Cancer Breakthrough Fund is a strategic move to strengthen Canada's entire life sciences ecosystem. The initiative arrives at a critical time, as recent reports from institutions like MaRS have highlighted a significant decline in early-stage venture capital for Canadian life sciences startups, which hold less than 5% of global biotech VC funding.

The fund counters this trend by introducing new sources of capital. Its investor base includes not only the founding charities but also a coalition of impact investors, foundations, and family offices, such as Rally Assets, Boann Social Impact, and Northpine Foundation. These investors are motivated by the dual mandate of generating strong financial returns and creating measurable social good.

"We believe the Cancer Breakthrough Fund does exactly this," said Lars Boggild, Portfolio Manager for Realize Fund I at Rally Assets. "It brings together the vision and networks of some of Canada's leading cancer philanthropies with the deep health sector investment expertise of Lumira Ventures. We believe this is a promising model for enabling the commercialization of mission-driven, Canadian solutions to the needs of cancer patients."

This injection of new, mission-aligned capital is expected to create a ripple effect, fostering a more robust domestic market for biotech investment. By helping promising young companies navigate the perilous journey from lab to market, the fund aims to build sustainable, globally competitive enterprises that create high-value jobs and anchor Canada's position as a leader in health innovation.

The Road Ahead: Investment and Impact

With the first close successfully completed, the fund's managers are moving forward with a clear strategy. The plan is to make approximately 13 investments in Canadian companies. A quarter of the fund’s capital is earmarked for early-stage companies, providing the critical seed financing that is currently in short supply. The remaining capital will be directed towards later-stage companies, often through co-investments with Lumira’s other funds, providing the scale-up capital needed for clinical trials and commercial launch.

This balanced approach ensures support across the development pipeline, from nascent ideas to market-ready products. Demonstrating its readiness to act, the fund has already approved its first investment in a Canadian company, though details have not yet been made public. This quick action underscores the urgency of the mission and the robust pipeline of opportunities that the partners have already identified.

As the Cancer Breakthrough Fund works toward its $50 million hard cap, it stands as a testament to a new era of collaborative innovation in Canada. By uniting the passion of philanthropy with the power of venture capital, the initiative is creating a formidable new weapon in the ongoing war against cancer, one that promises returns not just for investors, but for patients and the nation as a whole.